MedTrace Logo

A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

NCT06682806 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2026-02-02

No results posted yet for this study

Summary

This is a Phase 2 an open-label, multi-center study to determine the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PRT3789 in combination with pembrolizumab in patients with advanced, recurrent or metastatic solid tumors with a SMARCA4 mutation.

Conditions

  • Advanced Solid Tumor
  • Esophageal Cancer
  • Metastatic Solid Tumor
  • Non-small Cell Lung Cancers
  • SMARCA4 Gene Mutation

Interventions

DRUG

PRT3789

PRT3789 is administered as an intravenous infusion once weekly for 3 weeks

DRUG

pembrolizumab

Pembrolizumab is administered at 200 mg as an intravenous infusion over 30 min every 3 weeks

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-03
Primary Completion
2026-01-23
Completion
2026-01-23
FDA Drug
Yes

Countries

  • United States
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06682806 on ClinicalTrials.gov